BioMedNewsBreaks

ThursdayJun 22, 2023 10:50 am

BioMedNewsBreaks – Clene Inc. (NASDAQ: CLNN) Announces $40M Public Offering

Clene (NASDAQ: CLNN), along with its subsidiaries “Clene” and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative disease, recently announced the pricing of an underwritten public offering. The offering consists of 50,000,000 shares of its common stock and two tranches of warrants (each warrant to purchase one share of common stock) at a combined public offering price of $0.80 for each share of common stock and accompanying warrant. From the expected $40 million in gross proceeds from the offering, Clene intends to use the net proceeds, together with its existing…

Continue Reading

WednesdayJun 21, 2023 2:21 pm

BioMedNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Secures US Patent for SPU-21 Treatment for Autoimmune Disease

Silo Pharma (NASDAQ: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced that the U.S. Patent and Trademark Office (“USPTO”) has issued U.S. Patent 16/825,371 titled “Peptide-Targeted Liposomal Delivery for Treatment, Diagnosis and Imaging of Diseases and Disorders.” According to the announcement, the new patent claims cover the company’s portfolio drug SPU-21, a peptide-guided anti-arthritis drug, as a method of selectively targeting inflamed synovial tissue. “Our SPU-21 liposomal homing peptides, licensed from the University of Maryland, Baltimore, are able to identify markers of arthritic inflammation in joints and have potential for the development…

Continue Reading

WednesdayJun 21, 2023 10:53 am

BioMedNewsBreaks – Bone Biologics Corporation (NASDAQ: BBLG) Announces $5M Underwritten Public Offering

Bone Biologics (NASDAQ: BBLG), a developer of orthobiologic products for spine fusion markets, recently announced the pricing of an underwritten public offering of common stock. The company is selling 2,538,071 shares of its common stock in the offering, each at a price to the public of $1.97, for aggregate gross proceeds of approximately $5.0 million. In addition, Bone Biologics has granted the underwriters an over-allotment option, exercisable for a period of 45 days from the date of the underwriting agreement for the offering, to purchase up to an additional 253,807 common shares. Subject to customary conditions, the offering was expected…

Continue Reading

TuesdayJun 20, 2023 12:08 pm

BioMedNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Enters Agreement to Grant Exclusive Rights to Recreational Alcohol Misuse Technology

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, today announced its entry into a non-binding letter of intent. The agreement, dated June 19, 2023, is with 1319741 B.C. Ltd., which will be renamed “Celly Nutrition Inc.” (“Celly Nu”), an unlisted reporting issuer, and sets forth the basic terms and conditions upon which Celly Nu will be granted exclusive rights to recreational applications for FSD Pharma’s alcohol misuse technology designed to accelerate alcohol detoxification. FSD Pharma will…

Continue Reading

FridayJun 16, 2023 2:26 pm

BioMedNewsBreaks – Genprex Inc.’s (NASDAQ: GNPX) Flagship Candidate Could Potentially Reshape NSCLC Landscape

Genprex (NASDAQ: GNPX) is conducting its Phase 1/2 Acclaim-1 clinical trial evaluating the safety and efficacy of combining REQORSA(R), the company’s innovative drug candidate, in combination with Tagrisso(R) in patients with advanced EGFR mutant non-small cell lung cancer (“NSCLC”) who have experienced disease progression after previous treatments. “REQORSA Immunogene Therapy represents a potentially groundbreaking experimental drug that harnesses the power of genetic medicine to combat NSCLC,” a recent article explains. “During the Phase 1 portion of the clinical trial, the primary emphasis is on evaluating the safety of the treatment. However, the findings also have revealed promising efficacy results. One…

Continue Reading

ThursdayJun 15, 2023 10:09 am

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Participation in Upcoming Maxim Group Virtual Healthcare Conference

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, will be featured in an upcoming webcast fireside chat. The company announced that CEO John Climaco will present at the Healthcare Virtual Conference Part II; the event is presented by Maxim Group LLC and hosted by M-Vest. Climaco’s live, online presentation is slated for 2:30 p.m. ET June 21, 2023. The announcement noted that this year’s conference is focused on opportunities in the healthcare sector being driven by the exponential growth in knowledge and…

Continue Reading

MondayJun 12, 2023 1:42 pm

BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Leveraging Big Pharma Competencies to Bring Innovative Therapies to Market Quicker, at Lower Cost

BiondVax (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, recently published Q1 2023 financial results and provided a business update. “The Q1 2023 results were in line with analysts’ expectations. R&D expenses increased about $800,000 from Q1 2022, which BiondVax attributed to the initiation and ramp-up of R&D activities for its innovative nanosized VHH antibody (‘NanoAb’) platform. In particular, the company finalized a preclinical proof-of-concept study of its inhaled anti-COVID NanoAb drug, reporting in January that the therapy virtually eliminated the SARS-CoV-2 virus in the…

Continue Reading

ThursdayJun 08, 2023 2:09 pm

BioMedNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Adds Wealth of Expertise to Its Board with Appointments of Ken Nelson and Mark Strome

HeartBeam (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector electrocardiogram (“VECG”) platform intended for patient use at home, today announced the appointment of Ken Nelson and Mark Strome to its board of directors, effective as of June 5, 2023. Nelson is a 20-year digital health, medical device and remote patient monitoring executive and innovator. Strome brings experience combining over 40 years in the investment management and securities industry. “We are privileged to welcome two members with highly relevant backgrounds to HeartBeam’s board,” said Branislav Vajdic, Ph.D., HeartBeam CEO and founder. “Ken brings extensive experience…

Continue Reading

WednesdayJun 07, 2023 2:58 pm

BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Eyes Broad-Based Application Potential of ONCOPREX(R) Nanoparticle Delivery System

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes, recently announced that its research collaborators presented positive preclinical data for the NRPL2 tumor suppressor gene. “The studies used Genprex’s non-viral ONCOPREX(R) Nanoparticle Delivery System in KRAS/STK11 mutant anti-PD1 resistant metastatic human non-small cell lung cancer (‘NSCLC’) humanized mouse models. Genprex’s ONCOPREX(R) Nanoparticle Delivery System is a novel non-vital approach utilizing lipid nanoparticles to deliver tumor suppressor genes that have been deleted during the course of cancer development. The platform allows for intravenous delivery of various tumor suppressor genes, and potentially…

Continue Reading

TuesdayJun 06, 2023 2:50 pm

BioMedNewsBreaks – IGC Pharma Inc. (NYSE American: IGC) Receives Notice of Allowance for Patent on IGC-501

IGC Pharma (NYSE American: IGC) today announced its receipt of a Notice of Allowance from the Commissioner of Patents, Canada, for its patent filing on the use of cannabinoids in the treatment of seizures (“IGC-501”). The formulation additionally received an intent to grant from the European Patent Office. With these and a previous award, the formulation for treating seizures is protected in the U.S., Canada and certain European countries. IGC provided animal data (dogs) on the reduction in the number of seizures by using a combination of cannabidiol (“CBD”) and phenobarbital versus either alone. The company intends to pursue the…

Continue Reading